M
Maria Blasi
Researcher at Duke University
Publications - 42
Citations - 992
Maria Blasi is an academic researcher from Duke University. The author has contributed to research in topics: Medicine & Immunology. The author has an hindex of 11, co-authored 31 publications receiving 500 citations. Previous affiliations of Maria Blasi include Istituto Superiore di Sanità & Durham University.
Papers
More filters
Journal ArticleDOI
Fatty acid transport protein 2 reprograms neutrophils in cancer
Filippo Veglia,Vladimir A. Tyurin,Maria Blasi,Alessandra De Leo,Andrew V. Kossenkov,Laxminarasimha Donthireddy,Tsun Ki Jerrick To,Zach Schug,Subhasree Basu,Fang Wang,Emanuela Ricciotti,Concetta C. DiRusso,Maureen E. Murphy,Robert H. Vonderheide,Paul M. Lieberman,Charles Mulligan,Brian Nam,Neil Hockstein,Gregory A. Masters,Gregory A. Masters,Michael J. Guarino,Cindy Lin,Yulia Nefedova,Paul N. Black,Valerian E. Kagan,Dmitry I. Gabrilovich +25 more
TL;DR: It is reported that mouse and human PMN-MDSCs exclusively upregulate fatty acid transport protein 2 (FATP2), and FATP2 mediates the acquisition of immunosuppressive activity by PMn-M DSCs and represents a target to inhibit the functions of PMN, MDSCs selectively and to improve the efficiency of cancer therapy.
Journal ArticleDOI
Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer
Filippo Veglia,Vladimir A. Tyurin,Dariush Mohammadyani,Dariush Mohammadyani,Maria Blasi,Elizabeth K. Duperret,Laxminarasimha Donthireddy,Ayumi Hashimoto,Alexandr A. Kapralov,Andrew A. Amoscato,Roberto Angelini,Sima Patel,Kevin Alicea-Torres,David B. Weiner,Maureen E. Murphy,Judith Klein-Seetharaman,Esteban Celis,Valerian E. Kagan,Dmitry I. Gabrilovich +18 more
TL;DR: It is found that impaired cross-presentation in DCs is largely associated with defect in trafficking of peptide–MHC class I (pMHC) complexes to the cell surface, caused by the interaction of electrophilic lipids with chaperone heat shock protein 70.
Journal ArticleDOI
The use of viral vectors in vaccine development
TL;DR: This article presented an overview of pre-clinical and clinical data on recombinant viral vector vaccines and discussed the advantages and limitations of the different viral vector platforms, including DNA plasmid vaccines, mRNA vaccines, and recombinant virus vectors.
Journal ArticleDOI
Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques.
Donatella R.M. Negri,Donatella R.M. Negri,Maria Blasi,Celia C. LaBranche,Robert Parks,Harikrishnan Balachandran,Michelle A. Lifton,Xiaoying Shen,Thomas N. Denny,Guido Ferrari,Maria Fenicia Vescio,Hanne Andersen,David C. Montefiori,Georgia D. Tomaras,Hua-Xin Liao,Sampa Santra,Barton F. Haynes,Mary E. Klotman,Andrea Cara,Andrea Cara +19 more
TL;DR: It is demonstrated that an IDLV-Env-based vaccine induces functional, comprehensive, and durable immune responses in Rhesus macaques, which support further evaluation of IDLV as a new HIV-1 vaccine delivery platform.
Journal ArticleDOI
The use of viral vectors in vaccine development
TL;DR: This paper presented an overview of pre-clinical and clinical data on recombinant viral vector vaccines and discussed the advantages and limitations of the different viral vector platforms, including DNA plasmid vaccines, mRNA vaccines, and recombinant virus vectors.